Sanofi's First-in-Class OX40L mAb Succeeds in Two Key Phase III Trials

Sanofi has announced that its first-in-class OX40L-targeting monoclonal antibody (mAb), amlitelimab, met the primary endpoints in two Phase III trials (SHORE and COAST 2) for moderate-to-severe atopic dermatitis in adolescents and adults aged 12 and above. This follows a previous Phase III success in September 2025, positioning the drug as the most advanced OX40L inhibitor in development. Amlitelimab is designed to block the interaction between OX40L and its receptor to modulate immune response without depleting T-cells.

In the SHORE study, which evaluated amlitelimab in combination with topical therapies, both four-weekly and 12-weekly dosing regimens showed statistically significant improvements over placebo in validated Investigator Global Assessment and Eczema Area and Severity Index scores. The COAST 2 monotherapy study yielded similarly positive results. Based on the combined data from these trials, Sanofi plans to proceed with global regulatory submissions for the treatment of atopic dermatitis.

According to PharmCube's NextBiopharm® database, amlitelimab is under development in eight other immunology indications. Click here to request a free trial for NextBiopharm®.

Daily News
Abbott Pays USD 40mn Upfront for Disco AND-Gated Bispecific Option
2026-11-20
MegaRobo Raises USD 200mn to Scale Physical-World AI Infrastructure
2026-11-20
Novartis Enters ADC Arena With Over USD 2bn OBI Pharma Platform Deal
2026-11-19
Pfizer Licenses Starna's In Vivo CAR-T Platform for Up to USD 2.63bn
2026-11-19
Zelgen's CD3×DLL3 Trispecific Hits Pivotal Endpoint in Relapsed SCLC
2026-11-19
Latest Report
AI- in-BD- Portfolio
Details